Writing for ACNR
We welcome submissions from our UK and international readers. If you have an idea for an article or would like us to consider your work for publication, contact our editor…
General Rules
Authors should follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
The title and outline of the article will be agreed between the Editor and Contributor as will the length of the article.
The article will be scheduled to appear in a particular issue. However no guarantees, written or implied, can be given in this respect.
The contribution is non remunerable. There are no page charges for authors or their institutions.
The article will be sent to a peer reviewer, who may suggest amendments. The Editor also reserves the right to alter or amend the contribution. If this happens, we will return the article for reconsideration by the contributor and re-submission in its amended form.
The Editor’s decision will be final and binding. No undue correspondence will be entered into.
Copyright
Work submitted for publication must be original, previously unpublished, and not under consideration for publication elsewhere. If previously published figures, tables, or parts of text are to be included, the copyright-holder’s permission must have been obtained prior to submission, or ACNR must be given the necessary information to obtain copyright (figure number, page number, title and address of publication, copyright holder’s name and address). Authors retain their copyright for all articles published on-line.
Conflict of Interest
Authors are responsible for disclosing all conflicts of interest in their manuscript including financial, consultant, institutional, personal and other relationships between themselves and others that might bias their work. All source of funding should be acknowledged in the manuscript. To prevent ambiguity, any possible conflict of interest, financial or otherwise, related to the submitted article must be clearly indicated on the manuscript and if there is no conflict of interest this should be explicitly stated as none declared.
As confirmation, please complete our online disclosure form when submitting an article.
Related
Tom Foltynie
BSc, MBBS, MRCP, PhD
Professor Tom Foltynie is Professor of Neurology in the Department of Clinical and Movement Neurosciences, UCL Institute of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London. He is responsible for Movement disorder patients, particularly Parkinson’s disease (PD) patients undergoing advanced treatments such as Deep Brain Stimulation (DBS), Apomorphine and Duodopa. He is chief investigator for a series of trials of Exenatide- a potential neurorestorative treatment for PD, as well as the lead clinician at UCL for trials of alpha synuclein vaccination for PD and Oxford Biomedica/ Axovant’s gene therapy product for PD, and the Transeuro PD cell transplantation programme.
